MA32642B1 - Amides utiles en therapie - Google Patents

Amides utiles en therapie

Info

Publication number
MA32642B1
MA32642B1 MA33710A MA33710A MA32642B1 MA 32642 B1 MA32642 B1 MA 32642B1 MA 33710 A MA33710 A MA 33710A MA 33710 A MA33710 A MA 33710A MA 32642 B1 MA32642 B1 MA 32642B1
Authority
MA
Morocco
Prior art keywords
optionally substituted
substituents
alkyl
independently selected
oxo
Prior art date
Application number
MA33710A
Other languages
Arabic (ar)
English (en)
Inventor
Karl Richard Gibson
Martin Peter Green
Toby James Underwood
Florian Wakenhut
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of MA32642B1 publication Critical patent/MA32642B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un composé de formule (i), ou un sel ou un solvate pharmaceutiquement acceptables de celui-ci, (i) dans laquelle, r1 et r2 représentent chacun indépendamment h, un halogène, cf3, un alkyle en c1 à c3 ou un alcoxy en c1 à c3; r3 représente un alkyle en c1 à c6, un cycloalkyle en c3 à c6, un phényle (éventuellement substitués par un ou plusieurs substituants chacun indépendamment choisi parmi ra) ou het (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi oh, un oxo, ou un alkyle en c1 à c4); r4 représente h ou un alkyle en c1 à c3; r5 représente un alkyle en c1 à c6 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi rb), un cycloalkyle en c3 à c6 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi un oxo ou oh), ou het2 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi rd); un atome d'oxygène ou 1 atome de soufre, ou (c) 1 atome d'oxygène ou 1 atome de soufre, (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisis parmi oh, un oxo ou un alkyle en c1 à c4); et r6 représente un alkyle en c1 à c3 (éventuellement substitué par un ou plusieurs substituants chacun indépendamment choisi parmi rf), un cycloalkyle en c3 à c5 (éventuellement substitué par un ou plusieurs halogènes), cn ou un halogène; où rf représente un halogène ou un phényle. L'invention concerne également des compositions, des procédés de préparation, et des utilisations de celles-ci, par exemple dans le traitement de l'endométriose ou de fibromes utérins.
MA33710A 2008-09-18 2011-03-18 Amides utiles en therapie MA32642B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9790208P 2008-09-18 2008-09-18
PCT/IB2009/054038 WO2010032200A1 (fr) 2008-09-18 2009-09-16 Composés amides utiles en thérapie

Publications (1)

Publication Number Publication Date
MA32642B1 true MA32642B1 (fr) 2011-09-01

Family

ID=41269630

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33710A MA32642B1 (fr) 2008-09-18 2011-03-18 Amides utiles en therapie

Country Status (20)

Country Link
US (2) US8232269B2 (fr)
EP (1) EP2350017A1 (fr)
JP (1) JP2012502975A (fr)
KR (1) KR20110044304A (fr)
CN (1) CN102159548A (fr)
AP (1) AP2011005611A0 (fr)
AU (1) AU2009294290B2 (fr)
BR (1) BRPI0918935A2 (fr)
CA (1) CA2735931A1 (fr)
CL (1) CL2011000570A1 (fr)
CO (1) CO6351734A2 (fr)
DO (1) DOP2011000083A (fr)
EA (1) EA201100368A1 (fr)
EC (1) ECSP11010901A (fr)
IL (1) IL211479A0 (fr)
MA (1) MA32642B1 (fr)
MX (1) MX2011002899A (fr)
PE (1) PE20110793A1 (fr)
WO (1) WO2010032200A1 (fr)
ZA (1) ZA201102690B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921378B2 (en) * 2011-04-21 2014-12-30 Orion Corporation Androgen receptor modulating carboxamides
US9370521B2 (en) * 2011-07-21 2016-06-21 The Regents Of The University Of California Targeting GLI proteins in human cancer by small molecules
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
EP2700635A1 (fr) 2012-08-20 2014-02-26 Basf Se Dérivés d'amides de 5-trifluorométhylpyrazole en tant qu'herbicides
CA2898614C (fr) 2013-01-23 2021-10-26 The Regents Of The University Of California Ciblage de proteines gli a l'aide de petites molecules dans un cancer humain
HUE037192T2 (hu) 2013-02-22 2018-08-28 Pfizer Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
WO2014143617A1 (fr) * 2013-03-14 2014-09-18 Teva Women's Health, Inc. Tanaproget enrichi en deutérium et procédés de préparation associés
WO2016024185A1 (fr) 2014-08-12 2016-02-18 Pfizer Inc. Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
WO2017221144A1 (fr) * 2016-06-20 2017-12-28 Dr. Reddy's Laboratories Limited Procédé de préparation d'élagolix sodique et de son polymorphe
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3，3-二氟环丁烷甲酸的方法
KR20220100607A (ko) * 2019-10-28 2022-07-15 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 5원 헤테로사이클릭 옥소카르복실산 화합물 및 이의 의약 용도
CN118660877A (zh) * 2022-05-12 2024-09-17 西北农林科技大学 二苯基吡唑类化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604218A1 (fr) * 2005-04-20 2006-10-26 Pfizer Limited Derives de pyrazole tenant lieu d'antagonistes du recepteur de la progesterone
KR20080066938A (ko) * 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물

Also Published As

Publication number Publication date
EA201100368A1 (ru) 2011-12-30
KR20110044304A (ko) 2011-04-28
CN102159548A (zh) 2011-08-17
CA2735931A1 (fr) 2010-03-25
PE20110793A1 (es) 2011-10-31
EP2350017A1 (fr) 2011-08-03
ECSP11010901A (es) 2011-04-29
WO2010032200A1 (fr) 2010-03-25
US20120316150A1 (en) 2012-12-13
JP2012502975A (ja) 2012-02-02
AU2009294290B2 (en) 2012-08-30
BRPI0918935A2 (pt) 2015-12-01
AU2009294290A1 (en) 2010-03-25
US8232269B2 (en) 2012-07-31
AP2011005611A0 (en) 2011-04-30
DOP2011000083A (es) 2011-03-31
MX2011002899A (es) 2011-04-11
US20100249091A1 (en) 2010-09-30
CL2011000570A1 (es) 2011-06-17
CO6351734A2 (es) 2011-12-20
IL211479A0 (en) 2011-05-31
ZA201102690B (en) 2011-12-28

Similar Documents

Publication Publication Date Title
MA32642B1 (fr) Amides utiles en therapie
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
MY142807A (en) Benzimidazole derivative and use thereof.
EP1724262A4 (fr) Derive de 1-(2h)-isoquinolone
EA200801494A1 (ru) Производные оксадиазола с активностью crth2 рецептора
PE20040164A1 (es) Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas
TW200640862A (en) Pyridyl acetic acid compounds
MA30483B1 (fr) Utilisation de biphenylamides d'acide arylcarboxylique pour le traitement de semences.
MY150269A (en) Novel phenylpyrrole derivative
MA30724B1 (fr) Procede de preparation d'acide 4-amino-butyrique substitue par biaryle ou de derives de celui-ci et leur utilisation pour produire des inhibiteurs de nep.
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
MY177250A (en) Novel nicotinamide derivative or salt thereof
MA33851B1 (fr) Compose heterocyclique contenant de l'azote et fongicide agricole
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
DE602005005167D1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
CA2642211A1 (fr) Composes de 2,4-pyrimidinediamine pour le traitement ou la prevention de maladies autoimmunes
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR071792A1 (es) Antagonistas nitrogenados del receptor de glucagon, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento y/o prevencion de la diabetes tipo ii y afecciones relacionadas.
MA28973B1 (fr) Compose heterocyclique fusionne
NZ610312A (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
MA32089B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
MA32088B1 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique